New parenteral formulation of Celecoxib for the management of postoperative pain

最近的研究强调了COX2抑制剂作为阿片类药物的替代品在控制术后疼痛方面的价值，特别是塞来昔布的使用。由于其极低的水溶性，Celebrex仅以片剂形式提供，不能在手术期间和术后立即使用，因为不能使用片剂制剂。阿尔图斯配方公司是一家专门开发创新药物输送系统的制药公司。在他们的各种递送平台中，SmartCelle技术能够实现高度不溶性药物的非肠道递送。之前的动物研究已经强调了这项技术的潜力，因为结果表明了这种方法的通用性和耐受性。本项目旨在开发和验证术后疼痛模型，以评估新型止痛剂制剂的效力，并评估塞来昔布注射制剂在动物模型中的效力。TransBIOTech将首先通过测量动物对机械刺激的敏感性来评估目前使用的注射镇痛剂丁丙诺啡和酮洛酸对大鼠足底切开疼痛模型的反应。随后，塞来昔布新型注射制剂的效力将在足底切开模型中进行评估，并与酮咯酸进行比较。

Recent studies have highlighted the value of COX2 inhibitors as alternatives to opioids for the management of postoperative pain and, in particular, the use of Celecoxib. Due to its very low water solubility Celebrex is only available in tablet, precluding its use during and immediately after surgery when tablet formulations cannot be administered. Altus Formulation is a pharmaceutical company specialized in the development of innovative drug delivery systems. Among their various delivery platforms, the SmartCelle technology enables the parenteral delivery of highly insoluble drugs. Previous animal studies have highlighted the potential of the technology as results demonstrated the versatility and the tolerability of the approach. This project aims to develop and validate a postoperative pain model to evaluate the potency of novel analgesic formulations and to assess the potency of an injectable formulation of Celecoxib in the animal model. TransBIOTech will first evaluate the response to currently use injectable analgesics, buprenorphin and Ketorolac of the plantar incision pain model in the rat by measuring the sensitivity of the animals to mechanical stimulation. Afterward, the potency of the novel injectable formulation of Celecoxib will be evaluated in the plantar incision model and compared to Ketorolac.****